Preclinical and Clinical Evaluation of Carbohydrate Immunopharmaceuticals in the Prevention of Sepsis and Septic Sequelae
Document Type
Article
Publication Date
1-1-1995
Description
Sepsis and sepsis syndrome are significant causes of morbidity and mortality in critically ill patients. Despite technological and therapeutic advances in critical care, sepsis continues to be a pivotal factor in 20-50 % of deaths in surgical intensive care units. It is clear that alternative approaches to the prevention and/or treatment of sepsis must be found. Preclinical data indicate that macrophage activation with (1→3)-β-D-glucans will ameliorate sequelae associated with Gram-negative septicemia. Recent clinical data indicate that macrophage activation with (1→3)-β-D-glucans will significantly reduce septic morbidity and mortality in trauma and/or high-risk surgical patients. This work reviews the preclinical and clinical evaluation of (1→3)-β-D-glucans in the prevention of sepsis and septic sequelae.
Citation Information
Williams, D. L.; Mueller, A.; and Browder, W.. 1995. Preclinical and Clinical Evaluation of Carbohydrate Immunopharmaceuticals in the Prevention of Sepsis and Septic Sequelae. Journal of Endotoxin Research. Vol.2(3). 203-208. https://doi.org/10.1177/096805199500200309 ISSN: 0968-0519